Nateglinide

Generic Name
Nateglinide
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H27NO3
CAS Number
105816-04-4
Unique Ingredient Identifier
41X3PWK4O2
Background

Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.

Indication

For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-

A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

Phase 4
Completed
Conditions
First Posted Date
2005-10-13
Last Posted Date
2012-04-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
24
Registration Number
NCT00238472

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

First Posted Date
2005-09-21
Last Posted Date
2010-02-15
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
140
Registration Number
NCT00212290
Locations
🇺🇸

VA Puget Sound Health Care System (American Lake Campus), Tacoma, Washington, United States

🇺🇸

VA Puget Sound Health Care System (Seattle Campus), Seattle, Washington, United States

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

First Posted Date
2005-09-19
Last Posted Date
2008-03-13
Lead Sponsor
Astellas Pharma Inc
Registration Number
NCT00189774
© Copyright 2024. All Rights Reserved by MedPath